Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 10

1599P - Symptomatic skeletal events, health-related quality of life and pain in a phase III study of [177Lu]Lu-PSMA-617 in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer: Third interim analysis of PSMAfore

Date

14 Sep 2024

Session

Poster session 10

Topics

Clinical Research;  Therapy

Tumour Site

Prostate Cancer

Presenters

Karim Fizazi

Citation

Annals of Oncology (2024) 35 (suppl_2): S962-S1003. 10.1016/annonc/annonc1607

Authors

K. Fizazi1, M.J. Morris2, N.D. Shore3, K.N. Chi4, M. Crosby5, J.S. de Bono6, K. Herrmann7, G. Roubaud8, J. Nagarajah9, M.T. Fleming10, B. Lewis11, L.T. Nordquist12, D.E. Castellano Gauna13, N. Carnahan14, S. Ghebremariam15, M. Hertelendi16, O. Sartor17

Author affiliations

  • 1 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 2 Medicine Dept, MSKCC - Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 3 Department Of Urology, Carolina Urologic Research Center, 29572 - Myrtle Beach/US
  • 4 Medical Oncology Department, BC Cancer Agency - Vancouver, V5Z 4E6 - Vancouver/CA
  • 5 Veterans Prostate Cancer Awareness, Veterans Prostate Cancer Awareness Inc, 20005 - Washington DC/US
  • 6 Division Of Clinical Studies, Royal Marsden Hospital Institute of Cancer Research, SM2 5NG - Sutton/GB
  • 7 Nuclear Medicine Department, University Hospital Essen, 45147 - Essen/DE
  • 8 Medical Oncology, Institute Bergonié, 33000 - Bordeaux/FR
  • 9 Department Of Medical Imaging, Radboud University Medical Centre, 6525 GA - Nijmegen/NL
  • 10 Gu, Virginia Oncology Associates, 23502 - Norfolk/US
  • 11 Health Sciences Center, Tulane University, 70112 - New Orleans/US
  • 12 Medical Oncology, XCancer, Urology Cancer Center and GU Research Network, 68130 - Omaha/US
  • 13 Medical Oncology Department, Hospital Universitario 12 de Octubre, 28041 - Madrid/ES
  • 14 Development, Novartis Pharmaceuticals, 27560 - Morrisville/US
  • 15 Oncology, Novartis Pharmaceuticals Corporation, 07936 - East Hanover/US
  • 16 Medical Affairs, Novartis Pharmaceuticals Corporation, 4002 - Basel/CH
  • 17 Hematology/oncology Department, Mayo Clinic - Rochester, 55905 - Rochester/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1599P

Background

In PSMAfore (NCT04689828), [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged rPFS versus androgen receptor pathway inhibitor (ARPI) change in taxane-naive patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). We now present the time to symptomatic skeletal events (SSE) and time to worsening (TTW) in health-related quality of life (HRQoL) and pain at the third interim analysis (data cutoff, 27 Feb 2024).

Methods

Eligible patients had mCRPC, were candidates for ARPI change after one progression on previous ARPI, and had ≥1 PSMA-positive and no exclusionary PSMA-negative metastatic lesions by [68Ga]Ga-PSMA-11 PET/CT. Patients were randomized 1:1 to open-label 177Lu-PSMA-617 (7.4 GBq q6w; 6 cycles) or ARPI change (abiraterone/enzalutamide). Patients with confirmed radiographic progression on ARPI change could cross over to 177Lu-PSMA-617. The primary endpoint was rPFS. Other endpoints included time to SSE and TTW in self-reported HRQoL (FACT-P, EQ-5D-5L; secondary) and pain (BPI-SF; exploratory).

Results

In total, 468 patients (234/arm) were randomized. Median duration of exposure was 8.4 months for 177Lu-PSMA-617 and 6.5 months for ARPI change. 177Lu-PSMA-617 prolonged time to SSE and fewer bone fractures were reported versus ARPI change (4 [1.7%] vs 13 [5.6%]) (Table). 177Lu-PSMA-617 prolonged TTW in FACT-P, EQ-5D-5L and BPI-SF versus ARPI change (Table). Incidences of grade ≥3 adverse events (AEs), serious AEs and AEs leading to discontinuation for 177Lu-PSMA-617 and ARPI change were 36% and 48%, 20% and 32%, and 5.7% and 5.2%, respectively. Table: 1599P

177Lu-PSMA-617 (n = 234) ARPI change (n = 234) HR (95% CI)
Time to SSE or death, months, median (95% CI) NE (NE, NE) 17.97 (14.26, NE) 0.41 (0.26, 0.63)
SSE, n (%) 27 (11.5) 63 (26.9)
Pathological bone fracture 4 (1.7) 13 (5.6)
Spinal cord compression 6 (2.6) 4 (1.7)
Tumour-related orthopaedic surgical intervention 1 (0.4) 3 (1.3)
Radiation therapy to relieve bone pain 16 (6.8) 43 (18.4)
Death without SSE, n (%) 4 (1.7) 5 (2.1)
TTW, months, median (95% CI)
FACT-P total 7.46 (6.08, 8.54) 4.27 (3.45, 4.50) 0.61 (0.50, 0.75)
EQ-5D-5L utility score 6.28 (4.70, 7.89) 3.88 (3.25, 4.44) 0.67 (0.54, 0.82)
BPI-SF pain intensity 5.13 (4.11, 6.14) 3.65 (3.06, 4.34) 0.73 (0.59, 0.88)

DCO, 27 Feb 2024NE, not estimable

Conclusions

177Lu-PSMA-617 clinically meaningfully and significantly prolonged time to SSE and TTW in self-reported HRQoL and pain versus ARPI change in taxane-naive patients with PSMA-positive mCRPC.

Clinical trial identification

NCT04689828.

Editorial acknowledgement

Under direction of the authors, Sophie Adams, PhD, of Oxford PharmaGenesis, Oxford, UK provided medical writing support, which was funded by Novartis.

Legal entity responsible for the study

Novartis.

Funding

Novartis.

Disclosure

K. Fizazi: Financial Interests, Personal and Institutional, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Arvinas, CureVac, Macrogenics, Orion; Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Clovis, Daiichi Sankyo, Janssen, MSD, Novartis, Pfizer, Sanofi. M.J. Morris: Financial Interests, Institutional, Research Grant: Bayer; Progenics; Corcept Therapeutics; Roche/Genentech; Janssen; Celgene; Novartis; Astellas Pharma; Financial Interests, Personal, Speaker, Consultant, Advisor: Lantheus Medical Imaging, AstraZeneca, Amgen, Daiichi Sankyo, Convergent Therapeutics, Pfizer, ITM Isotope Technologies Munich, Clarity Pharmaceuticals, Blue Earth Diagnostics, POINT Biopharma, Telix Pharmaceuticals, Progenics, and Z-Alpha; Financial Interests, Personal, Other, Support for attending meetings and/or travel: AstraZeneca, APCCC, and Memorial Sloan-Kettering Cancer Center; Financial Interests, Personal, Stocks/Shares: Doximity. N.D. Shore: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Cold Genesys, Dendreon, Exact Imaging, Genesis Care Us, Invitae, Janssen, MDxhealth, Merck, Myovant, Myriad, Nymox, Pacific Edge, Pfizer, Propella, Sanofi Genzyme, Speciality Networks, Tolmar, Urogen, Clarity, Lantheus, Lilly, Photocure, Telix, Photocure, Asieris, Alessa Therapeutics, Arquer, Fize medical, GConcology, Guardant, Ferring, Foundation Medicine, Immunitybio, Incyte, Minomic, NGM, Nonagen, Novartis, PlatformQ, Promaxo, Protara, Accord, Antev, Aura biosciences, Sumitomo; Financial Interests, Personal, Member of Board of Directors: Photocure, Alessa Theraputics; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Bayer, Aura, Exact Imaging, Janssen, Merck, Myovant, Novartis, Pfizer, Propella, Bristol Myers Squibb, Dendreon, Pfizer, Urogen; Financial Interests, Institutional, Local PI: alessa, GC oncology, FORMA therapeutics, Pacific edge, Point Biopharma, The MT group, Theralase, Verity, Astellas, Palette Life Sciences, Steba, Zenflow. K.N. Chi: Financial Interests, Personal, Invited Speaker: Astellas, AstraZeneca, Janssen, Point Biopharma, Roche; Financial Interests, Personal, Advisory Board: AstraZeneca, AstraZeneca, Janssen, Merck, Novartis, Pfizer, Point Biopharma, Roche, BMS; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Janssen, Novartis, Roche; Financial Interests, Institutional, Trial Chair: AstraZeneca, Arvinas, Janssen, Novartis; Financial Interests, Institutional, Local PI: Arvinas. M. Crosby: Financial Interests, Personal, Steering Committee Member: Novartis; Financial Interests, Personal, Other, Consulting fees: Lantheus; Financial Interests, Personal, Other, Patient Advocacy Support Pfizer Patient Advocacy Support: Pfizer; Financial Interests, Personal, Other, Patient Advocacy Support Pfizer Patient Advocacy Support Pfizer Patient Advocacy Support: Johnson & Johnson; Financial Interests, Personal, Other, Patient Advocacy Support Pfizer Patient Advocacy Support: Sumitomo; Financial Interests, Personal, Other, Patient Advocacy Support: Astellas, AstraZeneca, BlueEarth Diagnostics, Boston Scientific, Elekta, Macrogenitcs, Profound Medical, Telix, Tempus, Tolmar; Financial Interests, Personal and Institutional, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Telix; Financial Interests, Personal and Institutional, Advisory Board, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Profind Medical, Pfizer, Johnson & Johnson; Financial Interests, Personal, Advisory Board: Telix; Financial Interests, Personal and Institutional, Advisory Board: Society of Nuclear Medicine and Molecular Imagin; Financial Interests, Personal and Institutional, Steering Committee Member: American Urological Association. J.S. de Bono: Financial Interests, Personal, Advisory Board: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Menarini Silicon Biosystems, ImCheck Therapeutics, Crescendo, MetaCurUm, Myricx, Nurix Therapeutics, Oncternal Therapeutics; Financial Interests, Institutional, Advisory Board: Harpoon, Dark Blue Therapeutics, Novartis, Takeda, Tango Therapeutics; Financial Interests, Institutional, Research Grant: Astellas, AstraZeneca, Bayer, Cellcentric, Daiichi Sankyo, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals, Crescendo Biologics, Menarini Silicon Biosystems, Immunic Therapeutics, MetaCurUm, Myricx, Nurix Therapeutics, Oncternal Therapeutics; Financial Interests, Institutional, Local PI: Amgen; Non-Financial Interests, Principal Investigator: Amgen, Astellas, AstraZeneca, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi Sankyo, Eisai, Genentech Roche, Genmab, GSK, Harpoon, Janssen, Menarini Silicon Biosystems, Merck Serono, Merck Sharp & Dohme, Orion Pharma, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo, Vertex Pharmaceuticals, Crescendo, ImCheck Therapeutics, Immunic Therapeutics; Non-Financial Interests, Institutional, Product Samples: Daiichi Sankyo, Bayer, Merck Serono, AstraZeneca, Harpoon, Pfizer, Sierra Oncology, Genentech/Roche, Sanofi Aventis, GSK. K. Herrmann: Financial Interests, Personal, Advisory Board: Bayer, Adacap/Novartis, Curium, Boston Scientific, GE Healthcare, AstraZeneca; Financial Interests, Personal, Invited Speaker: Sirtex, Siemens Healthineers, Monrol; Financial Interests, Personal, Other, Consultant: Amgen; Financial Interests, Personal, Other, DMSB: ymabs; Financial Interests, Personal, Advisory Board, Scientific Advisor: AdvanceCell; Financial Interests, Personal, Advisory Board, Advisor, Consultant: Janssen; Financial Interests, Personal, Advisory Board, Consultant: Eco1R, Fusion Pharmaceuticals, Genentech; Financial Interests, Personal, Member of Board of Directors: Sofie Biosciences, Pharma 15; Financial Interests, Personal, Ownership Interest: Sofie Biosciences; Financial Interests, Personal, Stocks/Shares: Aktis Oncology, AdvanCell, Convergent Therapeutics; Non-Financial Interests, Leadership Role, Chair Oncology&Theragnostics Committee: EANM. G. Roubaud: Financial Interests, Personal, Advisory Board: Janssen, Astellas, Bayer; Financial Interests, Institutional, Advisory Board: Pfizer, AstraZeneca; Financial Interests, Institutional, Invited Speaker: Novartis; Financial Interests, Institutional, Coordinating PI: Bayer. J. Nagarajah: Financial Interests, Personal and Institutional, Research Grant: Novartis, ABX; Financial Interests, Personal, Speaker, Consultant, Advisor: CURIUM, POINT Biopharma; Financial Interests, Personal and Institutional, Other, Payment of honoraria for lectures, presentations, speakers bureaus, manuscript writing, educational events: Bayer, AG, Pfizer. M.T. Fleming: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. D.E. Castellano Gauna: Financial Interests, Personal, Advisory Board: Pfizer, Roche, BMS, Janssen, Astellas, MSD, Ipsen, AstraZeneca, Novartis, GSK; Financial Interests, Institutional, Local PI: Pfizer, Roche, MSD, BMS, AstraZeneca, Janssen, Astellas, Ipsen, Exelisis, Eisai, Lilly, Bayer, GSK, Clovis, QED Therapeutics; Non-Financial Interests, Other, any: Associate Professor of Medical Oncology/Internal Medicine department; Non-Financial Interests, Personal, Other, Executive member: SOGUG (Spanish Oncology Genito-Urinary Group) Foundation; Non-Financial Interests, Personal, Training, Head of GU Alliance for Research and Development Consortium: GUARD Consortium; Other, any: Member of the Internal/local Pharmacy Commission at the Hospital Universitario 12 de Octubre. N. Carnahan: Financial Interests, Institutional, Full or part-time Employment: Novartis Pharmaceuticals. S. Ghebremariam: Financial Interests, Personal, Full or part-time Employment: Novartis. M. Hertelendi: Financial Interests, Personal, Full or part-time Employment: Novartis. O. Sartor: Financial Interests, Personal, Other, All support for the present manuscript: Novartis; Financial Interests, Institutional, Research Grant: Novartis, Amgen, Bayer, Endocyte, Invitae, Janssen, Lantheus, Merck, Progenics, Tenebio; Financial Interests, Institutional, Royalties: AstraZeneca; Financial Interests, Personal, Speaker, Consultant, Advisor: ARTBIO, AAA, AstraZeneca, Bayer, Blue Earth Diagnostics, Clarity Pharmaceuticals, Fusion, Isotope Technologies, Merck, Janssen, Myovant, Myriad, Noria Therapeutics, Novartis, NorthStar, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix; Financial Interests, Personal, Other, Support for attending meetings and travel: Lantheus, Novartis, NorthStar; Financial Interests, Personal, Advisory Board: AstraZeneca, Merck, Pfizer; Financial Interests, Personal, Stocks/Shares: ARTBIO, Ratio, Clarity Pharmaceuticals, Convergent, Fusion, Pfizer, Telix; Financial Interests, Personal, Stocks or ownership: Lilly. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.